The Optimal Use of Cabazitaxel for Prostate Cancer
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
Clinical Pearls
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
- More oncologists are becoming comfortable with using the cytotoxic chemotherapy cabazitaxel. It is only approved for use after docetaxel.
- After prescribing docetaxel to a patient with hormone-sensitive disease, a physician can then choose to administer docetaxel again or switch to cabazitaxel.
- Sequencing of abiraterone, enzalutamide, cabazitaxel, docetaxel, sipuleucel-T, and radium-223 is not entirely clear.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
